| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/20/1997 | CA2229068A1 Block polymer having functional groups on its both ends |
| 02/20/1997 | CA2228512A1 Peptide and o-glycan inhibitors of selectin mediated inflammation |
| 02/20/1997 | CA2227764A1 Composition for enhanced uptake of polar drugs from the colon |
| 02/19/1997 | EP0758645A1 Prostaglandin derivatives |
| 02/19/1997 | EP0758339A1 Increased bioavailability of biologically active compounds by linking to polypyrrolecarboxamidonaphthalene derivatives |
| 02/19/1997 | EP0758331A1 Polyethylene glycol derivatised dihydro or tetrahydro porphyrins, their preparation and their use as tumour localising, photosensitising compounds |
| 02/19/1997 | EP0758250A1 Texaphyrin solid-supports and devices |
| 02/19/1997 | EP0758249A1 Programmable genotoxic agents and uses therefor |
| 02/19/1997 | EP0758248A1 Formulations for factor ix |
| 02/19/1997 | EP0758244A1 Controlled-release dosage forms of azithromycin |
| 02/19/1997 | EP0758237A1 Lactone stable formulation of camptothecin or 7-ethyl camptothecin |
| 02/19/1997 | EP0758235A1 Polymer coated tablet comprising amoxycillin and clavulanate |
| 02/19/1997 | EP0758232A1 Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 02/19/1997 | EP0758231A1 Taxane class derivative based pharmaceutical compositions |
| 02/19/1997 | EP0758228A1 Effective dosage form for antiepileptic drugs |
| 02/19/1997 | EP0758227A1 Modulated release from biocompatible polymers |
| 02/19/1997 | EP0758226A1 Red blood cell surrogate |
| 02/19/1997 | EP0758198A1 Non-separable starch-oil compositions |
| 02/19/1997 | EP0730568A4 Amphiphilic derivatives of piperazine |
| 02/19/1997 | EP0730405A4 Amphiphilic derivatives of guanidine |
| 02/19/1997 | EP0730404A4 Amphiphilic imidazolinium derivatives |
| 02/19/1997 | CN1143374A Non-viral vector |
| 02/19/1997 | CN1143325A Method for selective methionine starvation of malignant cells in mammals |
| 02/19/1997 | CN1143324A Novel pharmaceutical composition for skin diseases |
| 02/19/1997 | CN1143320A Sublingual or buccal pharmaceutical composition |
| 02/19/1997 | CN1143318A Transdermal device containing polyvinylpyrrolidone as solubility ehancer |
| 02/19/1997 | CN1143317A Oral vehicle composition |
| 02/19/1997 | CN1142973A Vaccine composition having antitumour activity and use thereof in therapy of malignant diseases |
| 02/19/1997 | CN1034086C Heteropolysaccharide S-657 |
| 02/19/1997 | CN1034054C Preparing method for improved oligosaccharide conjugate vaccines |
| 02/19/1997 | CA2183400A1 Low-odor, higher molecular weight polyether polyols, a process for producing them, and their use for the production of polymers, cosmetics and pharmaceutical products synthesized from polyether polyols |
| 02/18/1997 | US5604233 Water soluble antitumor, anticancer agent |
| 02/18/1997 | US5604206 Complexes containing S(+) phenyl alkane acids and amino sugars |
| 02/18/1997 | US5604198 Parenterally administering conjugate consisting of neurologically active compound conjugated to carrier molecule permeable across said barrier |
| 02/18/1997 | US5604092 Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein |
| 02/18/1997 | US5603958 Pharmaceutical carrier |
| 02/18/1997 | US5603957 Microcapsules for the controlled release of acetylsalicyclic acid in the gastrointestinal environment |
| 02/18/1997 | US5603951 Cyclosporin-containing soft capsule compositions |
| 02/18/1997 | US5603943 Physiologically active substance homogeneously dispersed in and adsorbed on polyvalent metal carrier of specified particle size |
| 02/18/1997 | US5603940 Oil-in-water emulsion which may be used for obtaining a cream |
| 02/18/1997 | US5603929 Storage stable composition including acidic ophthalmic agent, antimicrobial polymeric quaternary ammonium compound, boric acid, vehicle |
| 02/17/1997 | CA2183015A1 Composition and method for treating prostate cancer |
| 02/13/1997 | WO1997005491A1 Stabilized aqueous steroid immunoassay standards with cyclodextrins |
| 02/13/1997 | WO1997005267A2 Mucosal delivery of polynucleotides |
| 02/13/1997 | WO1997005266A1 Methods and means for targeted gene delivery |
| 02/13/1997 | WO1997005185A2 Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents |
| 02/13/1997 | WO1997004813A1 Cellulose diacetate compositions for use in embolizing blood vessels |
| 02/13/1997 | WO1997004809A1 Sulfonated multiblock copolymer and uses therefor |
| 02/13/1997 | WO1997004807A1 Methods for treatment of allergic asthma |
| 02/13/1997 | WO1997004796A1 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations |
| 02/13/1997 | WO1997004795A2 Pharmaceutical compositions containing cyclosporin or other peptide substances |
| 02/13/1997 | WO1997004759A1 Transdermal patch containing aspirin |
| 02/13/1997 | WO1997004755A1 Hard gelatin capsules with low water transport and process for the production thereof |
| 02/13/1997 | WO1997004753A1 Pharmaceutical compositions of conjugated estrogens and methods for their use |
| 02/13/1997 | WO1997004752A1 Pharmaceutical compositions of conjugated estrogens and methods for their use |
| 02/13/1997 | WO1997004744A1 Polymeric drug formulations |
| 02/13/1997 | WO1997004657A1 Novel embolizing compositions |
| 02/13/1997 | WO1997004656A1 Novel compositions for use in embolizing blood vessels |
| 02/13/1997 | WO1997002003A3 Compositions |
| 02/13/1997 | WO1997001324A3 Cosmetic and/or pharmaceutical preparations |
| 02/13/1997 | WO1997000671A3 Composition for preparing finely dispersed systems and process for preparing the same |
| 02/13/1997 | WO1996041646A3 Pharmaceutical compositions containing lornoxicam and cyclodextrin |
| 02/13/1997 | WO1996040086A3 Compositions and methods for topical administration of pharmaceutically active agents |
| 02/13/1997 | WO1996040058A3 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir |
| 02/13/1997 | WO1996032133A3 Conjugate for treating inflammatory, infectious and/or skin diseases |
| 02/13/1997 | WO1996020012A3 Methods for preparing and purifying macromolecular conjugates |
| 02/13/1997 | DE19529223A1 Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau Use of plasminogen activators to the local bone formation |
| 02/13/1997 | CA2745743A1 Stabile isotonic lyophilized protein formulation |
| 02/13/1997 | CA2228118A1 Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents |
| 02/13/1997 | CA2228034A1 Transdermal patch containing aspirin |
| 02/13/1997 | CA2227871A1 Mucosal delivery of polynucleotides |
| 02/13/1997 | CA2226624A1 Methods for treatment of allergic asthma |
| 02/13/1997 | CA2224907A1 Methods and means for targeted gene delivery |
| 02/13/1997 | CA2215311A1 Cellulose diacetate compositions for use in embolizing blood vessels |
| 02/13/1997 | CA2215272A1 Novel compositions for use in embolizing blood vessels |
| 02/12/1997 | EP0758006A1 Process for passivating a photoreactive mineral pigment by an organic cold plasma treatment and lightfast cosmetic or pharmaceutical composition containing at least one thus passivated pigment |
| 02/12/1997 | EP0757911A1 New galenic formulations containing fenofibrate and their applications |
| 02/12/1997 | EP0757910A1 Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom |
| 02/12/1997 | EP0757690A1 Electron-deficient porphyrins and processes and intermediates for preparing same |
| 02/12/1997 | EP0757688A1 Method for stabilizing compound dx-52-1 and lyophilized composition thereof |
| 02/12/1997 | EP0470184B1 Antibodies specific for cd4-binding domain of hiv |
| 02/12/1997 | CN1142833A Poly-beta-1-4-N-acetylglucosamine |
| 02/12/1997 | CN1142776A Hirudin conjugates from hirudin and lipophilic compounds |
| 02/12/1997 | CN1142772A Parathyroid hormone formulation |
| 02/12/1997 | CN1142764A Sucrose ester C-zo to C-28 alcohol formulations |
| 02/12/1997 | CN1142748A Coprocessed galactomannan-glucomannan |
| 02/11/1997 | US5602240 Backbone modified oligonucleotide analogs |
| 02/11/1997 | US5602165 Transdermal absorptive drug formulation |
| 02/11/1997 | US5602148 Polyethylene glycol as a solubilizer |
| 02/11/1997 | US5602112 Pharmaceutical formulation |
| 02/11/1997 | US5601990 Methods of diagnosing colorectal tumors and metastasis thereof |
| 02/11/1997 | US5601981 Methods for determining and agents for modulating cellular redox potential and genotoxic states |
| 02/11/1997 | US5601845 Cores containing diltiazem(or salt) and microcrystalline cellulose coated with ethyl cellulose, for controlled release oral drug delivery |
| 02/11/1997 | US5601842 Analgesics; contains a non-moisture sensitive matrixing agent |
| 02/11/1997 | US5601839 Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| 02/11/1997 | US5601838 Method for treating pain associated with herpes-zoster and post-herpetic neuralgia |
| 02/11/1997 | US5601836 Nutritional supplement for calving ruminant animals |
| 02/11/1997 | US5601827 Replacing or deleting certain codons of naturally-occuring diphtheria toxin |
| 02/11/1997 | US5601825 Therapeutic conjugates of toxins and drugs |
| 02/11/1997 | CA2048924C Teat treating compositions, production and use |